Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

DZD6008

Phase 1Small molecule

DDizal Pharmaceuticals

DZD6008 is one of 100 small molecule programs targeting Lung Carcinoma. It is currently in Phase 1.

3

Indications

4

Total Trials

4

Active Trials

99

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CarcinomaRecruiting

Non-Small Cell Lung CancerRecruiting

Advanced NSCLCRecruiting

Lung CarcinomaPhase 1

Recruiting

Non-Small Cell Lung CancerPreclinical

Recruiting

Advanced NSCLCPhase 1

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

RC148

RRemeGen Co., Ltd.

Anktiva

SSWOG Cancer Research Network

Carboplatin/paclitaxel

Remeron

OOrganon and Co

Valemetostat Tosylate

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Advanced NSCLC

NCT06905197

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT07079475

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT07070440

Phase 1Recruiting

Lung Carcinoma

NCT06813365

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combined With Sunvozertinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN8)

Recruiting·DDizal (Jiangsu) Pharmaceutical Co., Ltd.·Preclinical·NCT07079475·220 enrolled

A Phase 1/2, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Recruiting·DDizal Pharmaceuticals·Preclinical·NCT07070440·180 enrolled

Advanced NSCLC1 trial

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Recruiting·DDizal Pharmaceuticals·Phase 1·NCT06905197·140 enrolled

Lung Carcinoma1 trial

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutation (TIAN-SHAN2)

Recruiting·DDizal Pharmaceuticals·Phase 1·NCT06813365·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for DZD6008. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DZD6008 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DZD6008. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dizal Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDizal Pharmaceuticals

Related News